Related Experiment Video
Updated: Aug 5, 2026

Evaluation of Caspase Activation to Assess Innate Immune Cell Death
Published on: January 20, 2023
IFN-α and IFN-β inhibit NLRP1-driven PANoptosis
Bhesh Raj Sharma1, Harisankeerth Mummareddy1, Sangappa B Chadchan1
1Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN, 38105, USA.
Abstract:
Pathogens, tissue damage, and cellular stress are detected by innate immune sensor molecules to drive inflammatory signaling and cell death. Mutations in the sensor NLRP1 are associated with inflammatory disease, but the regulation of this sensor is not well understood. Here, we find that LPS, a TLR4 ligand and canonical activator of innate immunity, inhibits NLRP1-mediated caspase activation, IL-18 release, and inflammatory cell death, PANoptosis. This inhibition requires TRIF but not MyD88, implicating TRIF-dependent TLR signaling. IRF3 is also required, suggesting an essential role for type I IFN signaling. Indeed, IFN-β production or treatment with exogenous IFN-α or IFN-β inhibits NLRP1-dependent PANoptosis in mouse bone marrow-derived macrophages and human macrophages and monocytes. Mechanistically, Nlrp1b/NLRP1 expression is significantly reduced in LPS- or type I IFN-treated cells. Overall, our study identifies a TLR4-TRIF-IRF3 signaling axis that induces type I IFNs to negatively regulate NLRP1 transcription, thereby blocking NLRP1-driven, caspase-1/caspase-8/RIPK3-dependent PANoptosis. These findings suggest type I IFNs as a potential therapeutic strategy for NLRP1-driven inflammatory diseases.
Insights
Toll-like receptor 4 (TLR4) signaling inhibits NLRP1-mediated PANoptosis, a form of inflammatory cell death. This pathway involves TRIF and IRF3, leading to type I interferons that suppress NLRP1 expression.
Area of Science:
- Immunology
- Cellular Biology
- Molecular Medicine
Background:
- Innate immune sensors like NLRP1 detect cellular stress and pathogens, initiating inflammatory signaling and cell death.
- Mutations in NLRP1 are linked to inflammatory diseases, yet its regulatory mechanisms remain unclear.
Purpose of the Study:
- To investigate the regulation of NLRP1-mediated inflammatory cell death (PANoptosis).
- To identify signaling pathways that modulate NLRP1 activity in response to innate immune activators.
Main Methods:
- Utilized lipopolysaccharide (LPS) as a Toll-like receptor 4 (TLR4) ligand to activate innate immunity.
- Assessed caspase activation, IL-18 release, and PANoptosis in response to LPS and interferons (IFNs).
- Investigated the roles of TRIF, MyD88, and IRF3 in the signaling pathway.
- Quantified NLRP1 expression in response to LPS and type I IFNs in murine and human immune cells.
Main Results:
- LPS inhibits NLRP1-mediated PANoptosis, caspase activation, and IL-18 release.
- This inhibition is dependent on TRIF and IRF3, indicating a role for TRIF-dependent TLR4 signaling and type I IFN signaling.
- Type I IFNs (IFN-α, IFN-β) directly inhibit NLRP1-dependent PANoptosis in macrophages and monocytes.
- LPS and type I IFNs significantly reduce NLRP1 and Nlrp1b expression at the transcriptional level.
Conclusions:
- A TLR4-TRIF-IRF3 signaling axis induces type I IFNs, which suppress NLRP1 transcription.
- This negative feedback loop blocks NLRP1-driven PANoptosis, involving caspase-1, caspase-8, and RIPK3.
- Type I IFNs represent a potential therapeutic target for managing NLRP1-associated inflammatory diseases.
Related Concept Videos
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
The Extrinsic Apoptotic Pathway
The Intrinsic Apoptotic Pathway
